[go: up one dir, main page]

NO2007007I2 - Pioglitazon/Glimepiride - Google Patents

Pioglitazon/Glimepiride

Info

Publication number
NO2007007I2
NO2007007I2 NO2007007C NO2007007C NO2007007I2 NO 2007007 I2 NO2007007 I2 NO 2007007I2 NO 2007007 C NO2007007 C NO 2007007C NO 2007007 C NO2007007 C NO 2007007C NO 2007007 I2 NO2007007 I2 NO 2007007I2
Authority
NO
Norway
Prior art keywords
glimepiride
pioglitazone
Prior art date
Application number
NO2007007C
Other languages
English (en)
Other versions
NO2007007I1 (no
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15563926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2007007(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO2007007I1 publication Critical patent/NO2007007I1/no
Publication of NO2007007I2 publication Critical patent/NO2007007I2/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO2007007C 1995-06-20 2007-06-04 Pioglitazon/Glimepiride NO2007007I2 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15350095 1995-06-20

Publications (2)

Publication Number Publication Date
NO2007007I1 NO2007007I1 (no) 2007-06-18
NO2007007I2 true NO2007007I2 (no) 2009-10-05

Family

ID=15563926

Family Applications (5)

Application Number Title Priority Date Filing Date
NO19962606A NO313226B1 (no) 1995-06-20 1996-06-19 Farmasöytisk sammensetning som omfater en insulinsensitivitetsenhancer i kombinasjon med eninsulinsekresjonsenhancer og anvendelse av disse
NO20004345A NO314065B1 (no) 1995-06-20 2000-09-01 Farmasöytisk sammensetning omfattende en insulinsensitivitetsenhancer og etbiguanid ved behandling av diabetes
NONO/SPC/2A NO317341B1 (no) 1995-06-20 2002-03-08 Vorikonazol
NO2007001C NO2007001I2 (no) 1995-06-20 2007-01-04 Pioglitazon/metformin.
NO2007007C NO2007007I2 (no) 1995-06-20 2007-06-04 Pioglitazon/Glimepiride

Family Applications Before (4)

Application Number Title Priority Date Filing Date
NO19962606A NO313226B1 (no) 1995-06-20 1996-06-19 Farmasöytisk sammensetning som omfater en insulinsensitivitetsenhancer i kombinasjon med eninsulinsekresjonsenhancer og anvendelse av disse
NO20004345A NO314065B1 (no) 1995-06-20 2000-09-01 Farmasöytisk sammensetning omfattende en insulinsensitivitetsenhancer og etbiguanid ved behandling av diabetes
NONO/SPC/2A NO317341B1 (no) 1995-06-20 2002-03-08 Vorikonazol
NO2007001C NO2007001I2 (no) 1995-06-20 2007-01-04 Pioglitazon/metformin.

Country Status (26)

Country Link
US (44) US5952356A (no)
EP (6) EP1174135B2 (no)
JP (3) JP3148973B2 (no)
KR (3) KR970000233A (no)
CN (3) CN1289082C (no)
AR (4) AR005641A1 (no)
AT (2) ATE438397T1 (no)
CA (3) CA2533845C (no)
CY (4) CY2424B1 (no)
CZ (2) CZ291624B6 (no)
DE (4) DE69631157T2 (no)
DK (2) DK1174135T3 (no)
ES (2) ES2212208T3 (no)
FR (1) FR09C0055I2 (no)
HK (1) HK1041203B (no)
HU (1) HUP9601698A3 (no)
LU (2) LU91298I2 (no)
MX (1) MX9602399A (no)
MY (1) MY127530A (no)
NL (2) NL300258I2 (no)
NO (5) NO313226B1 (no)
PT (2) PT1174135E (no)
RU (5) RU2327455C2 (no)
SK (2) SK287351B6 (no)
TW (2) TW438587B (no)
ZA (1) ZA965190B (no)

Families Citing this family (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
EP0851757A2 (en) 1995-08-10 1998-07-08 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
KR19990087076A (ko) * 1996-04-05 1999-12-15 다께다 구니오 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물
ES2250283T3 (es) 1996-07-15 2006-04-16 Sankyo Company Limited Uso de cs-866 (olmesartan) en la preparacion de un medicamento para el tratamiento de la arteriosclerosis.
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
AU778947B2 (en) * 1997-06-18 2004-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
JP2001523271A (ja) * 1997-06-18 2001-11-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チアゾリジンジオンおよびアルファ−グルコシダーゼ阻害剤を用いる糖尿病の治療
PL337510A1 (en) * 1997-06-18 2000-08-28 Smithkline Beecham Plc Treatment of diabetes by means of derivatives of thiazolydinone and sulphonylurea
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
AP1279A (en) * 1997-06-18 2004-05-20 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin.
AU783539B2 (en) * 1997-06-18 2005-11-10 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
AU782419B2 (en) * 1997-07-18 2005-07-28 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
AU740299B2 (en) * 1997-10-20 2001-11-01 Dainippon Sumitomo Pharma Co., Ltd. Fast-dissolving pharmaceutical composition
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
EP1093370B1 (en) * 1998-06-30 2006-02-22 Takeda Pharmaceutical Company Limited Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DE69818444T2 (de) 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
EP1126844A1 (en) 1998-10-29 2001-08-29 The Board Of Regents, The University Of Texas System Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
EA200601145A1 (ru) * 1998-11-12 2009-04-28 Смитклайн Бичам П.Л.С. Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
AP1692A (en) * 1998-11-12 2006-12-12 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
DK1143955T3 (da) * 1998-12-24 2005-11-14 Metabasis Therapeutics Inc En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
WO2000044554A1 (en) * 1999-01-29 2000-08-03 Takeda Chemical Industries, Ltd. Compressing mallet with coating treatment
JP4799720B2 (ja) * 1999-01-29 2011-10-26 武田薬品工業株式会社 コーティング処理を施した打錠用杵
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
CN101165036A (zh) * 1999-04-01 2008-04-23 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
JP2000355550A (ja) * 1999-04-14 2000-12-26 Takeda Chem Ind Ltd ケトーシス改善剤
ATE247653T1 (de) * 1999-04-23 2003-09-15 Smithkline Beecham Plc Thiazolidindionderivat und seine verwendung als antidiabetikum
GB9910693D0 (en) * 1999-05-07 1999-07-07 Univ Liverpool A compound for use in medicine
US6214842B1 (en) * 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
CA2377246A1 (en) * 1999-06-18 2000-12-28 Ranjit C. Desai Arylthiazolidinedione and aryloxazolidinedione derivatives
SI1133312T1 (sl) 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
AU5760900A (en) * 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
CA2377309C (en) * 1999-06-30 2010-11-23 Tularik Inc. Compounds for the modulation of ppar.gamma. activity
AU779730B2 (en) * 1999-06-30 2005-02-10 Amgen, Inc. Compounds for the modulation of PPARgamma activity
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2386379C (en) * 1999-10-06 2009-12-15 Toshio Miyata Carbonyl stress-decreasing agent
EP1218015A2 (en) * 1999-10-08 2002-07-03 Novartis AG Pharmaceutical composition of nateglinide and another antidiabetic agent
US6274622B1 (en) * 1999-10-27 2001-08-14 Frederick H. Hausheer Method of treating diabetic ophthalmopathy
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
CN1450902A (zh) 1999-11-03 2003-10-22 布里斯托尔-迈尔斯斯奎布公司 包含二甲双胍和格列本脲组合的药用组合物
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US6660021B1 (en) 1999-12-23 2003-12-09 Advanced Cardiovascular Systems, Inc. Intravascular device and system
US6575997B1 (en) 1999-12-23 2003-06-10 Endovascular Technologies, Inc. Embolic basket
US6402771B1 (en) 1999-12-23 2002-06-11 Guidant Endovascular Solutions Snare
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
JP2003518493A (ja) * 1999-12-24 2003-06-10 スミスクライン ビーチャム パブリック リミテッド カンパニー 新規治療方法
US6695813B1 (en) 1999-12-30 2004-02-24 Advanced Cardiovascular Systems, Inc. Embolic protection devices
US7918820B2 (en) 1999-12-30 2011-04-05 Advanced Cardiovascular Systems, Inc. Device for, and method of, blocking emboli in vessels such as blood arteries
US6540722B1 (en) 1999-12-30 2003-04-01 Advanced Cardiovascular Systems, Inc. Embolic protection devices
US20010036479A1 (en) * 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
WO2001052860A2 (en) * 2000-01-24 2001-07-26 Inotek Corporation Method and composition for modulating an immune response
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
AU2001232244A1 (en) * 2000-02-10 2001-08-20 Takeda Chemical Industries Ltd. Drug comprising combination
CA2401356A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Combination drug
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6461639B2 (en) 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US6939362B2 (en) * 2001-11-27 2005-09-06 Advanced Cardiovascular Systems, Inc. Offset proximal cage for embolic filtering devices
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6964670B1 (en) 2000-07-13 2005-11-15 Advanced Cardiovascular Systems, Inc. Embolic protection guide wire
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
EP1325745B1 (en) * 2000-10-12 2008-07-23 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
US6537294B1 (en) 2000-10-17 2003-03-25 Advanced Cardiovascular Systems, Inc. Delivery systems for embolic filter devices
US6893451B2 (en) 2000-11-09 2005-05-17 Advanced Cardiovascular Systems, Inc. Apparatus for capturing objects beyond an operative site utilizing a capture device delivered on a medical guide wire
US6506203B1 (en) 2000-12-19 2003-01-14 Advanced Cardiovascular Systems, Inc. Low profile sheathless embolic protection system
BRPI0206432A2 (pt) 2001-01-12 2016-10-25 Sun Pharmaceutical Ind Ltd métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
DE60204611T2 (de) 2001-02-28 2006-05-11 Pfizer Products Inc., Groton Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren
MXPA03007451A (es) * 2001-03-02 2004-10-15 Lichtwer Pharma Ag Medicamento para tratar la diabetes mellitus.
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
WO2002079198A1 (en) 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
EP1374869A1 (en) * 2001-04-03 2004-01-02 Yamanouchi Pharmaceutical Co. Ltd. Novel use of arylethene sulfonamide derivative
DK1377276T3 (da) * 2001-04-10 2012-01-02 Sun Pharma Advanced Res Co Ltd Beregning af puls-frigivelsessammensætning
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US7338510B2 (en) 2001-06-29 2008-03-04 Advanced Cardiovascular Systems, Inc. Variable thickness embolic filtering devices and method of manufacturing the same
US6599307B1 (en) 2001-06-29 2003-07-29 Advanced Cardiovascular Systems, Inc. Filter device for embolic protection systems
JP2004536843A (ja) * 2001-07-10 2004-12-09 エアロファーム テクノロジー インコーポレイテッド ピオグリタゾンおよびビグアナイドを含むコア製剤
EP1429732A4 (en) * 2001-07-10 2005-01-26 Kos Life Sciences Inc CORE FORMULATION
US6638294B1 (en) 2001-08-30 2003-10-28 Advanced Cardiovascular Systems, Inc. Self furling umbrella frame for carotid filter
US6592606B2 (en) 2001-08-31 2003-07-15 Advanced Cardiovascular Systems, Inc. Hinged short cage for an embolic protection device
US8262689B2 (en) 2001-09-28 2012-09-11 Advanced Cardiovascular Systems, Inc. Embolic filtering devices
AU2002349705A1 (en) 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7241304B2 (en) 2001-12-21 2007-07-10 Advanced Cardiovascular Systems, Inc. Flexible and conformable embolic filtering devices
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
AU2003235120A1 (en) * 2002-04-26 2003-11-10 Takeda Chemical Industries, Ltd. Screening method
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US6887258B2 (en) 2002-06-26 2005-05-03 Advanced Cardiovascular Systems, Inc. Embolic filtering devices for bifurcated vessels
US7172614B2 (en) 2002-06-27 2007-02-06 Advanced Cardiovascular Systems, Inc. Support structures for embolic filtering devices
EP1549296A4 (en) 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co METFORMIN FORMULATIONS WITH DELAYED RELEASE
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004026241A2 (en) 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
US7252675B2 (en) 2002-09-30 2007-08-07 Advanced Cardiovascular, Inc. Embolic filtering devices
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040088000A1 (en) 2002-10-31 2004-05-06 Muller Paul F. Single-wire expandable cages for embolic filtering devices
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
IN192749B (no) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
US7976853B2 (en) * 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US8591540B2 (en) 2003-02-27 2013-11-26 Abbott Cardiovascular Systems Inc. Embolic filtering devices
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
JP3819415B2 (ja) * 2003-04-09 2006-09-06 日本たばこ産業株式会社 複素芳香５員環化合物及びその医薬用途
US7820158B2 (en) * 2003-04-10 2010-10-26 Surmodics, Inc. Ligand-coupled initiator polymers and methods of use
ES2421520T3 (es) * 2003-04-28 2013-09-03 Daiichi Sankyo Co Ltd Potenciador de la producción de adiponectina
CA2524175C (en) * 2003-04-28 2016-06-14 Sankyo Company Limited Sugar intake-ability enhancer
WO2004101560A1 (en) * 2003-05-13 2004-11-25 Synthon B.V. Processes for making thiazolidinedione derivatives and compounds thereof
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
KR20060105431A (ko) * 2003-06-27 2006-10-11 닥터 레디스 리서치 파운데이션 발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1651251A4 (en) * 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20070004623A1 (en) * 2003-10-27 2007-01-04 Innodia Inc. Use of hydroxylated amino acids for treating diabetes
PT1677792E (pt) * 2003-10-31 2016-02-09 Takeda Pharmaceutical Preparação sólida compreendendo pioglitazona, glimepirida e um éster de ácido gordo de polioxietileno sorbitano
US7892251B1 (en) 2003-11-12 2011-02-22 Advanced Cardiovascular Systems, Inc. Component for delivering and locking a medical device to a guide wire
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
US7360069B2 (en) * 2004-01-13 2008-04-15 Hewlett-Packard Development Company, L.P. Systems and methods for executing across at least one memory barrier employing speculative fills
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
EP1714648A4 (en) * 2004-02-09 2010-05-26 Aska Pharm Co Ltd COMBINATION DRUGS
EP1716144A2 (en) * 2004-02-20 2006-11-02 Synthon B.V. Processes for making pioglitazone and compounds of the processes
JP2007526309A (ja) * 2004-03-02 2007-09-13 アベール ファーマシューティカルズ インコーポレイテッド 生物活性剤の混合製剤またはキット
US7678129B1 (en) 2004-03-19 2010-03-16 Advanced Cardiovascular Systems, Inc. Locking component for an embolic filter assembly
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
JP2008514549A (ja) * 2004-09-14 2008-05-08 エリクシアー ファーマシューティカルズ， インコーポレイテッド 制御された炭水化物消化のための併用療法
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
US9259305B2 (en) 2005-03-31 2016-02-16 Abbott Cardiovascular Systems Inc. Guide wire locking mechanism for rapid exchange and other catheter systems
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
KR100964330B1 (ko) * 2005-07-07 2010-06-17 학교법인 포항공과대학교 당흡수 조절제 및 당뇨병 또는 당뇨병 합병증의 치료방법
CA2614664A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obesity,metabolic syndrome and polycystic ovary syndrome
CA2615975C (en) * 2005-07-22 2012-11-27 The Procter & Gamble Company Compositions for reducing the incidence of drug induced arrhythmia
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
RU2426530C2 (ru) 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007105730A1 (ja) * 2006-03-13 2007-09-20 Kyowa Hakko Kogyo Co., Ltd. インスリン抵抗性改善剤
EP2001468B1 (en) 2006-03-16 2012-10-31 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
KR20080106455A (ko) * 2006-03-31 2008-12-05 웰스태트 테러퓨틱스 코포레이션 대사장애의 조합치료
BRPI0710141B1 (pt) * 2006-04-11 2018-02-06 Sorbwater Technology As Método para remoção de poluentes de uma corrente aquosa contínua, solução apropriada para adição a uma corrente aquosa, uso do método e mistura para adicionar a uma corrente aquosa poluída
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2037928B1 (en) 2006-06-26 2012-01-11 Amgen Inc. Methods for treating atherosclerosis
US7752724B2 (en) * 2006-06-27 2010-07-13 Lumino, Inc. Method of cutting blinds
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
WO2008091624A2 (en) * 2007-01-22 2008-07-31 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
US8455432B2 (en) 2007-01-25 2013-06-04 Verva Pharmaceuticals Ltd. Insulin sensitisers and methods of treatment
HRP20110094T8 (en) * 2007-02-01 2011-07-31 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and pioglitazone
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8216209B2 (en) 2007-05-31 2012-07-10 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
RU2345771C1 (ru) * 2007-06-19 2009-02-10 Илья Николаевич Медведев Способ нормализации тромбопластинообразования у больных метаболическим синдромом
US7867273B2 (en) 2007-06-27 2011-01-11 Abbott Laboratories Endoprostheses for peripheral arteries and other body vessels
ES2449483T3 (es) 2007-07-26 2014-03-19 Amgen, Inc Enzimas lecitina-colesterol aciltransferasa modificadas
NZ583889A (en) * 2007-09-14 2012-01-12 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension
WO2009038107A1 (ja) * 2007-09-21 2009-03-26 Kissei Pharmaceutical Co., Ltd. ２型糖尿病治療用の組合せ医薬
WO2009073627A1 (en) * 2007-11-30 2009-06-11 The Research Foundation Of State University Of New York Metabolic fuel switching biomarker
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
EP2190417A2 (en) * 2008-03-26 2010-06-02 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CN104611421B (zh) * 2008-08-12 2018-08-07 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2010105103A1 (en) 2009-03-11 2010-09-16 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20110038848A1 (en) 2009-08-12 2011-02-17 Melaleuca, Inc. Dietary supplement compositions for cardiovascular health
BR112012011237A2 (pt) 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
RU2607453C2 (ru) * 2009-12-04 2017-01-10 Сенхва Байосайенсиз, Инк. Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы
ES2617704T3 (es) * 2009-12-15 2017-06-19 Octeta Therapeutics, Llc Tiazolidindionas ahorradoras de PPAR y combinaciones para el tratamiento de enfermedades neurodegenerativas
CA2783468C (en) * 2009-12-15 2018-10-09 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
US20140088027A1 (en) 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
AU2011237775A1 (en) * 2010-04-06 2012-11-22 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
RU2526153C2 (ru) * 2010-07-15 2014-08-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
WO2012028934A1 (en) 2010-09-01 2012-03-08 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201390421A1 (ru) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
DK2665477T3 (en) * 2011-01-20 2015-12-14 Bionevia Pharmaceuticals Inc MODIFIED RELEASE COMPOSITIONS OF EPAL REST OR A DERIVATIVE THEREOF AND PROCEDURES FOR USING THE SAME
WO2013034174A1 (en) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
CN104220460A (zh) 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
RU2572706C1 (ru) * 2014-06-30 2016-01-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
EP3253382B1 (en) 2015-02-06 2021-11-17 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
WO2018130679A1 (en) 2017-01-16 2018-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN112955964B (zh) 2018-06-14 2023-10-27 阿斯利康(英国)有限公司 用二甲双胍药物组合物降低血糖的方法
CA3142358A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
JP2023528726A (ja) 2020-04-01 2023-07-06 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法
JP2023528565A (ja) 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
CN112869173A (zh) * 2021-01-18 2021-06-01 广州富诺营养科技有限公司 一种复合维生素矿物质制剂及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5728073A (en) * 1980-07-29 1982-02-15 Takeda Chem Ind Ltd Inhibitor for aldose reducing enzyme
US4863922A (en) * 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
WO1988006887A1 (en) * 1987-03-20 1988-09-22 Alcon Laboratories, Inc. Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
JPH0466579A (ja) * 1990-07-04 1992-03-02 Yamanouchi Pharmaceut Co Ltd チアゾリジン誘導体
JPH0469383A (ja) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
US5260275A (en) 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2686861B2 (ja) * 1991-03-30 1997-12-08 キッセイ薬品工業株式会社 新規なベンジリデンコハク酸誘導体
AU1743292A (en) * 1991-04-11 1992-11-17 Takeda Chemical Industries Ltd. Thiazolidinedione derivatives, production and use thereof
ATE151634T1 (de) * 1991-08-26 1997-05-15 Upjohn Co Flüssiges nahrungsmittel, das 3- guanidinopropionsäure enthält
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
JPH07316144A (ja) * 1994-03-29 1995-12-05 Sankyo Co Ltd ジフェニルメチルピペラジン誘導体
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6001049A (en) * 1998-02-12 1999-12-14 Frey; Mark P. Light weight exercise apparatus

Also Published As

Publication number Publication date
HK1010484A1 (en) 1999-06-25
US6103742A (en) 2000-08-15
US6271243B1 (en) 2001-08-07
US6121294A (en) 2000-09-19
CN1530106A (zh) 2004-09-22
JP3973280B2 (ja) 2007-09-12
FR09C0055I1 (no) 2009-04-12
EP0861666A3 (en) 1999-02-10
US20030216443A1 (en) 2003-11-20
DE122007000002I2 (de) 2012-03-08
LU91606I2 (fr) 2009-11-09
EP1174135B2 (en) 2016-09-14
DE122007000002I1 (de) 2012-03-08
US6166043A (en) 2000-12-26
ES2327383T5 (es) 2017-03-13
CA2179584A1 (en) 1996-12-21
HK1041203B (en) 2009-09-25
EP1174135A2 (en) 2002-01-23
AR005641A1 (es) 1999-07-14
SK287287B6 (sk) 2010-05-07
ES2327383T3 (es) 2009-10-29
PT861666E (pt) 2004-05-31
DE69637988D1 (de) 2009-09-17
RU2223760C2 (ru) 2004-02-20
US6911459B2 (en) 2005-06-28
SK79496A3 (en) 1997-01-08
US7144900B2 (en) 2006-12-05
US6133293A (en) 2000-10-17
JP4809806B2 (ja) 2011-11-09
HUP9601698A3 (en) 2000-09-28
JP3148973B2 (ja) 2001-03-26
EP1764110A1 (en) 2007-03-21
NO2007001I2 (no) 2011-03-14
US20110034518A1 (en) 2011-02-10
JP2007191494A (ja) 2007-08-02
CA2179584C (en) 2007-04-24
EP0749751A2 (en) 1996-12-27
AU5603496A (en) 1997-01-09
NO2007001I1 (no) 2007-01-29
TWI238064B (en) 2005-08-21
NL300258I1 (nl) 2007-04-02
US6150383A (en) 2000-11-21
US6156773A (en) 2000-12-05
US6303640B1 (en) 2001-10-16
DK1174135T3 (da) 2009-12-07
US20090246232A1 (en) 2009-10-01
US6232330B1 (en) 2001-05-15
US6329404B1 (en) 2001-12-11
DE122009000064I1 (de) 2011-12-01
US6150384A (en) 2000-11-21
AU723097B2 (en) 2000-08-17
EP0861666A2 (en) 1998-09-02
RU2327455C2 (ru) 2008-06-27
LU91298I2 (fr) 2007-02-20
KR20070081135A (ko) 2007-08-16
CN1212117C (zh) 2005-07-27
US6323225B1 (en) 2001-11-27
US6274605B1 (en) 2001-08-14
US6080765A (en) 2000-06-27
US6211207B1 (en) 2001-04-03
CN1289082C (zh) 2006-12-13
NO962606D0 (no) 1996-06-19
US6169100B1 (en) 2001-01-02
US6288090B1 (en) 2001-09-11
KR20080005162A (ko) 2008-01-10
RU2286148C2 (ru) 2006-10-27
US6239153B1 (en) 2001-05-29
CY2608B2 (en) 2010-04-28
TW438587B (en) 2001-06-07
RU2323004C2 (ru) 2008-04-27
US6172090B1 (en) 2001-01-09
DK0861666T3 (da) 2004-03-08
US6211205B1 (en) 2001-04-03
CZ292093B6 (cs) 2003-07-16
AR061195A2 (es) 2008-08-13
NO317341B1 (no) 2004-10-11
EP0749751A3 (en) 1997-04-16
US7538125B2 (en) 2009-05-26
US6277869B1 (en) 2001-08-21
EP2292268A1 (en) 2011-03-09
CA2533845A1 (en) 1996-12-21
RU2198682C2 (ru) 2003-02-20
US6174904B1 (en) 2001-01-16
PT1174135E (pt) 2009-08-31
HK1041203A1 (en) 2002-07-05
EP1174135B9 (en) 2009-12-16
CY2009018I1 (el) 2010-07-28
CN1530105A (zh) 2004-09-22
ES2212208T3 (es) 2004-07-16
NL300258I2 (nl) 2007-05-01
CY2007001I2 (el) 2009-11-04
FR09C0055I2 (fr) 2010-06-11
ATE256463T1 (de) 2004-01-15
US5952356A (en) 1999-09-14
NL300432I2 (en) 2010-04-01
NO20004345D0 (no) 2000-09-01
US6218409B1 (en) 2001-04-17
CZ181196A3 (en) 1997-01-15
US20070203198A1 (en) 2007-08-30
US5965584A (en) 1999-10-12
HUP9601698A2 (hu) 1997-05-28
AR065389A2 (es) 2009-06-03
EP1174135B1 (en) 2009-08-05
SK287351B6 (sk) 2010-08-09
NO2007007I1 (no) 2007-06-18
EP2289556A2 (en) 2011-03-02
EP2289556A3 (en) 2011-03-09
ATE438397T1 (de) 2009-08-15
CZ291624B6 (cs) 2003-04-16
CA2531834C (en) 2006-12-05
CY2009018I2 (el) 2010-07-28
US6166042A (en) 2000-12-26
US20020128289A1 (en) 2002-09-12
US20020042434A1 (en) 2002-04-11
EP1174135A3 (en) 2002-06-19
CY2007001I1 (el) 2009-11-04
NO313226B1 (no) 2002-09-02
CA2531834A1 (en) 1996-12-21
US20020123512A1 (en) 2002-09-05
NO20021172D0 (no) 2002-03-08
JPH0967271A (ja) 1997-03-11
US6169099B1 (en) 2001-01-02
MY127530A (en) 2006-12-29
CY2424B1 (en) 2004-11-12
CA2533845C (en) 2012-10-09
US20020002186A1 (en) 2002-01-03
US6172089B1 (en) 2001-01-09
US6121295A (en) 2000-09-19
JPH10167986A (ja) 1998-06-23
DE69631157D1 (de) 2004-01-29
US6251924B1 (en) 2001-06-26
NO314065B1 (no) 2003-01-27
HU9601698D0 (en) 1996-08-28
US7842706B2 (en) 2010-11-30
US20040266830A1 (en) 2004-12-30
US6384062B1 (en) 2002-05-07
NL300432I1 (en) 2010-03-01
DE69631157T2 (de) 2004-09-09
US6599923B2 (en) 2003-07-29
MX9602399A (es) 1997-02-28
NO20021172L (no) 1996-12-23
ZA965190B (en) 1997-12-19
NO20004345L (no) 1996-12-23
US6211206B1 (en) 2001-04-03
AR091289A2 (es) 2015-01-28
US6214848B1 (en) 2001-04-10
US6133295A (en) 2000-10-17
US6225326B1 (en) 2001-05-01
US20050054685A1 (en) 2005-03-10
NO962606L (no) 1996-12-23
EP0861666B1 (en) 2003-12-17
RU2003130978A (ru) 2005-04-20
KR970000233A (ko) 1997-01-21
CN1145783A (zh) 1997-03-26

Similar Documents

Publication Publication Date Title
NO2007007I1 (no) Pioglitazon/glimepiride
FI950047A0 (fi) Radiosystem foer traodloes abonnentanslutning
DE69626325D1 (de) Einlegesohle
ATA135896A (de) Skibob
ATE198470T1 (de) Alkenyl-benzoylguanidine
FI973755A7 (fi) Viistokantaniitti
ATE240972T1 (de) Cyclopeptolide
ATA119896A (de) Scheibenmähwerk
BR9501643A (pt) Helistato
FR2732104B1 (fr) Repose-fleches
KR960028533U (ko) ＂t＂ 자
FI2103U1 (fi) Sanitetsystem
BR7502937U (pt) Floco-decantador multicone
BR7501299U (pt) Geladeira-prática
BR7502653U (pt) Publi-taxi
BR7502098U (pt) T-compacto
BR7502025U (pt) Kantil
BR7501939U (pt) Caixa-ambalgem
BR7501858U (pt) Tellelight
BR7501836U (pt) Protecheque
BR7501828U (pt) Multicopo
BR7501485U (pt) Fibropiso
BR7501467U (pt) Vassourágua
BR7501437U (pt) Leiteira
BR7501426U (pt) Búlica